858 reports of this reaction
2.5% of all VALBENAZINE reports
#10 most reported adverse reaction
THERAPEUTIC PRODUCT EFFECT DECREASED is the #10 most commonly reported adverse reaction for VALBENAZINE, manufactured by Neurocrine Biosciences, Inc.. There are 858 FDA adverse event reports linking VALBENAZINE to THERAPEUTIC PRODUCT EFFECT DECREASED. This represents approximately 2.5% of all 34,810 adverse event reports for this drug.
Patients taking VALBENAZINE who experience therapeutic product effect decreased should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
THERAPEUTIC PRODUCT EFFECT DECREASED is a less commonly reported adverse event for VALBENAZINE, but still significant enough to appear in the safety profile.
In addition to therapeutic product effect decreased, the following adverse reactions have been reported for VALBENAZINE:
The following drugs have also been linked to therapeutic product effect decreased in FDA adverse event reports:
THERAPEUTIC PRODUCT EFFECT DECREASED has been reported as an adverse event in 858 FDA reports for VALBENAZINE. This does not prove causation, but indicates an association observed in post-market surveillance data.
THERAPEUTIC PRODUCT EFFECT DECREASED accounts for approximately 2.5% of all adverse event reports for VALBENAZINE, making it a notable side effect.
If you experience therapeutic product effect decreased while taking VALBENAZINE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.